164 related articles for article (PubMed ID: 1659595)
1. Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment.
Smyth RL; Scott JP; Borysiewicz LK; Sharples LD; Stewart S; Wreghitt TG; Gray JJ; Higenbottam TW; Wallwork J
J Infect Dis; 1991 Dec; 164(6):1045-50. PubMed ID: 1659595
[TBL] [Abstract][Full Text] [Related]
2. Should heart-lung transplant donors and recipients be matched according to cytomegalovirus serologic status?
Novick RJ; Menkis AH; McKenzie FN; Reid KR; Ahmad D
J Heart Transplant; 1990; 9(6):699-706. PubMed ID: 2177496
[TBL] [Abstract][Full Text] [Related]
3. Treatment of cytomegalovirus pneumonia in transplant patients.
Reed EC
Transplant Proc; 1991 Apr; 23(2 Suppl 1):8-12. PubMed ID: 1647562
[No Abstract] [Full Text] [Related]
4. Treatment and prophylaxis of cytomegalovirus disease.
Levinson ML; Jacobson PA
Pharmacotherapy; 1992; 12(4):300-18. PubMed ID: 1325636
[TBL] [Abstract][Full Text] [Related]
5. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus infections in heart and heart-lung transplant recipients.
Wreghitt T
J Antimicrob Chemother; 1989 Jun; 23 Suppl E():49-60. PubMed ID: 2550412
[TBL] [Abstract][Full Text] [Related]
7. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections.
Grob JP; Grundy JE; Prentice HG; Griffiths PD; Hoffbrand AV; Hughes MD; Tate T; Wimperis JZ; Brenner MK
Lancet; 1987 Apr; 1(8536):774-6. PubMed ID: 2882184
[TBL] [Abstract][Full Text] [Related]
8. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
Shah T; Lai WK; Mutimer D
Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
[TBL] [Abstract][Full Text] [Related]
9. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.
Nguyen Q; Champlin R; Giralt S; Rolston K; Raad I; Jacobson K; Ippoliti C; Hecht D; Tarrand J; Luna M; Whimbey E
Clin Infect Dis; 1999 Mar; 28(3):618-23. PubMed ID: 10194088
[TBL] [Abstract][Full Text] [Related]
10. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients.
Keay S; Petersen E; Icenogle T; Zeluff BJ; Samo T; Busch D; Newman CL; Buhles WC; Merigan TC
Rev Infect Dis; 1988; 10 Suppl 3():S563-72. PubMed ID: 2847294
[TBL] [Abstract][Full Text] [Related]
11. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
12. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
[TBL] [Abstract][Full Text] [Related]
13. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation.
Drobyski WR; Knox KK; Carrigan DR; Ash RC
Transplantation; 1991 Jul; 52(1):155-7. PubMed ID: 1650043
[No Abstract] [Full Text] [Related]
14. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients.
Aschan J; Ringdén O; Ljungman P; Lönnqvist B; Ohlman S
Scand J Infect Dis; 1992; 24(2):143-50. PubMed ID: 1322557
[TBL] [Abstract][Full Text] [Related]
15. Effect of CMV-immunoglobulins (cytotect biotest) prophylaxis on CMV pneumonia after lung transplantation.
Solidoro P; Delsedime L; Costa C; Bergallo M; Libertucci D; Ruffini E; Rinaldi M; Baldi S
New Microbiol; 2011 Jan; 34(1):33-6. PubMed ID: 21344144
[TBL] [Abstract][Full Text] [Related]
16. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants.
Bailey TC; Trulock EP; Ettinger NA; Storch GA; Cooper JD; Powderly WG
J Infect Dis; 1992 Mar; 165(3):548-52. PubMed ID: 1311352
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with the development of cytomegalovirus infection following solid organ transplantation.
da Cunha-Bang C; Sørensen SS; Iversen M; Sengeløv H; Hillingsø JG; Rasmussen A; Mortensen SA; Fox ZV; Kirkby NS; Christiansen CB; Lundgren JD
Scand J Infect Dis; 2011 May; 43(5):360-5. PubMed ID: 21306196
[TBL] [Abstract][Full Text] [Related]
18. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.
Merigan TC; Renlund DG; Keay S; Bristow MR; Starnes V; O'Connell JB; Resta S; Dunn D; Gamberg P; Ratkovec RM
N Engl J Med; 1992 Apr; 326(18):1182-6. PubMed ID: 1313549
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products.
Rubie H; Attal M; Campardou AM; Gayet-Mengelle C; Payen C; Sanguignol F; Calot JP; Charlet JP; Robert A; Huguet F
Bone Marrow Transplant; 1993 Mar; 11(3):209-14. PubMed ID: 8385522
[TBL] [Abstract][Full Text] [Related]
20. Fatal cytomegalovirus pneumonia after preemptive antiviral therapy in a renal transplant recipient.
Ketteler M; Preuschof L; Mertz A; Stöffler-Meilicke M; Schäfer H; Distler A; Offermann G
Clin Nephrol; 2000 Nov; 54(5):418-24. PubMed ID: 11105806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
